Stock Analysis on Net
Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying user area

Try for free

Boston Scientific Corp. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Boston Scientific Corp., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Net income (loss)
(Gain) loss on disposal of businesses and assets
Depreciation and amortization
Deferred and prepaid income taxes
Stock-based compensation expense
Goodwill and other intangible asset impairment charges
Net (gain) loss on investments and notes receivable
Contingent consideration net expense (benefit)
Inventory step-up amortization
Debt extinguishment costs
Other, net
Trade accounts receivable
Inventories
Other assets
Accounts payable, accrued expenses and other liabilities
Increase (decrease) in operating assets and liabilities, excluding purchase accounting
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities
Cash provided by (used for) operating activities (legacy)
Cash provided by (used for) operating activities
Purchases of property, plant and equipment and internal use software
Proceeds from sale of property, plant and equipment
Payments for acquisitions of businesses, net of cash acquired
(Payments for) proceeds from investments and acquisitions of certain technologies
Proceeds from disposal of certain businesses and assets
Proceeds from royalty rights
(Payments for) proceeds from settlements of hedge contracts
Cash (used for) provided by investing activities
Payment of contingent consideration previously established in purchase accounting
Payments for royalty rights
Proceeds from royalty rights transfer
Payments on short-term borrowings
Proceeds from short-term borrowings, net of debt issuance costs
Net increase (decrease) in commercial paper
Payments on borrowings from credit facilities
Proceeds from borrowings on credit facilities
Payments on long-term borrowings and debt extinguishment costs
Proceeds from long-term borrowings, net of debt issuance costs
Cash dividends paid on preferred stock
Net proceeds from issuance of preferred stock in connection with public offering
Net proceeds from issuance of common stock in connection with public offering
Payments for repurchase of common stock
Cash used to net share settle employee equity awards
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans
Cash provided by (used for) financing activities
Effect of foreign exchange rates on cash
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Cash flow statement item Description The company
Cash provided by (used for) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Boston Scientific Corp. cash provided by (used for) operating activities increased from Q3 2022 to Q4 2022 but then decreased significantly from Q4 2022 to Q1 2023.
Cash (used for) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Boston Scientific Corp. cash (used for) provided by investing activities increased from Q3 2022 to Q4 2022 but then decreased significantly from Q4 2022 to Q1 2023.
Cash provided by (used for) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Boston Scientific Corp. cash provided by (used for) financing activities increased from Q3 2022 to Q4 2022 but then slightly decreased from Q4 2022 to Q1 2023.